), a 2005 spinout from the  UK Health Protection Agency, has entered into a research and license  arrangement with Allergan (Irvine,   CA, 

). Under the agreement, the  companies will jointly fund research to use Syntaxin’s technology to engineer  clostridial endopeptidase-based proteins for cell targeting. This agreement  follows an earlier collaboration between the two companies in the field of  pain.

News

Syntaxin Ltd. (Wiltshire, UK, www.syntaxin.com), a 2005 spinout from the UK Health Protection Agency, has entered into a research and license arrangement with Allergan (Irvine, CA, www.allergan.com).